Cancer Fundamentals: Pathology, Staging, and Medical Management
What the exam expects
Pathology describes the tissue of origin, histologic subtype, grade (degree of differentiation), and molecular features. Staging describes anatomic spread. The TNM system (tumor size/invasion, node involvement, metastasis) is mapped to stages I–IV through cancer-specific rules, so identical TNM descriptors can produce different stages in different diseases - a favorite trap. Grade is not stage: a high-grade, node-negative tumor may still be stage I.
Equally important is treatment intent: curative, neoadjuvant, adjuvant, or palliative, plus which line of therapy the client is on. Intent and phase shape exercise timing and goals far more than a stage number does.
Modalities include surgery, cytotoxic chemotherapy, radiotherapy, endocrine therapy, targeted therapy, immunotherapy, and transplant. Learn one characteristic toxicity per class: anthracyclines → cardiomyopathy; bleomycin → pulmonary fibrosis; taxanes and platinum agents → peripheral neuropathy; androgen deprivation and aromatase inhibitors → bone loss; checkpoint inhibitors → immune-related adverse events.
Worked example
A client reports "stage IIIB breast cancer, on adjuvant paclitaxel, finished radiation." Correct reading: curative intent, currently in the adjuvant cytotoxic phase, with taxane neuropathy and fatigue as the likely limiting toxicities. The program should be modified for neuropathy fall risk and fatigue, not restricted because of the stage label.
Rule of thumb
When a stem gives you a stage, ask what else it tells you - intent, current phase, expected toxicity - and let those drive the answer.